Streetbeat News

Earnings

SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) hosted an investor event to discuss neffy, an investigational epinephrine nasal spray for severe Type I allergic reactions. The event highlighted the unmet need in the current epinephrine market, with a significant portion of patients not using their prescribed treatments correctly. neffy's potential benefits include effectiveness, safety, ease of use, and rapid action. ARS Pharma plans to resubmit a response to the FDA's Complete Response Letter in Q2 2024, aiming for a launch in the second half of 2024. The company also anticipates a decision from the European Medicines Agency in Q2 2024 and is developing neffy for urticaria treatment.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:36 pm

RBT

Rubicon Technologies (NYSE:RBT) reported Q4 2023 earnings with a GAAP EPS of $(0.340), surpassing the $(0.420) estimate. Sales reached $170.663M, exceeding the $169.750M forecast and marking a 2.81% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:35 pm

NAPA

Duckhorn Portfolio (NYSE:NAPA) reported its Q2 earnings on March 7, 2024, with an EPS of $0.18, matching the estimate but showing a revenue decrease of $443 thousand from the previous year. This follows a pattern of missed EPS estimates in the past, notably last quarter, which led to a 12% drop in share price the following day.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 9:35 pm

IMMR

Immersion (NASDAQ:IMMR) reported Q4 earnings of $0.49 per share, surpassing the $0.16 estimate, a 206.25% beat, and a 8.89% increase from last year. Q4 sales were $10.38M, beating the $8.22M estimate by 26.28%, and marking a 13.27% increase from the previous year.

Portfolio Pulse from Happy Mohamed

March 07, 2024 | 9:35 pm

DOMO

Domo (NASDAQ:DOMO) reported Q4 2024 GAAP EPS of $(0.050), meeting analyst estimates, with a 150% decrease in losses compared to last year. Sales reached $80.184M, surpassing the $79.538M estimate, marking a 0.70% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:34 pm

MACK

Merrimack Pharmaceuticals reported a Fiscal Year 2023 Earnings Per Share (EPS) of $(0.08) per basic share, indicating a loss.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:34 pm

IOT

Samsara has projected its FY25 adjusted EPS to be between $0.11 and $0.13, surpassing the estimated $0.08. The company also forecasts revenue to be between $1.186 billion and $1.196 billion, slightly above the $1.179 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:33 pm

COST

Costco Wholesale Corporation (NASDAQ:COST) reported its Q2 earnings with a revenue of $58.44 billion, missing the consensus estimate of $59.16 billion, but exceeded EPS expectations with $3.92 against an estimate of $3.61. Net sales increased by 5.7% year-over-year to $57.33 billion, affected by the fiscal calendar shift. Comparable sales saw growth across all regions, with e-commerce up by 18.2%. Costco ended the quarter with 872 warehouses globally. After the report, COST shares dropped 4.26% in after-hours trading.

Portfolio Pulse from Chris Katje

March 07, 2024 | 9:32 pm

IOT

Samsara has projected its Q1 2025 adjusted earnings per share (EPS) to be between $0.00 and $0.01, surpassing the estimated $(0.01). The company also forecasts its revenue to be between $271 million and $273 million, exceeding the estimated $266.838 million. This indicates a positive outlook for Samsara's financial performance in the near future.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:32 pm

WLDN

Willdan Group (WLDN) reported Q4 2023 adjusted EPS of $0.800, surpassing the $0.380 estimate, and sales of $80.772M, exceeding the $63.785M estimate. This represents a 25.10% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:32 pm